NanoViricides (NNVC) News Today $1.64 +0.09 (+5.81%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.63 -0.01 (-0.43%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock NNVC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period NanoViricides Completes $2 Million Registered Direct OfferingMay 20 at 6:51 PM | tipranks.comNanoViricides closes $2M direct offeringMay 19, 2026 | proactiveinvestors.comThe Bundibugyo strain of the Ebola virus: What do we know?May 18, 2026 | reuters.comEbola Global Health Emergency Needs a Broad-Spectrum Drug – NV-387 is a Strong Potential Candidate, Says NanoViricidesMay 18, 2026 | usatoday.comNanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreakMay 18, 2026 | proactiveinvestors.comNanoViricides, Inc. Has Filed its Quarterly Report – NV-387 Advancing for Phase IIMay 15, 2026 | usatoday.comNanoViricides to raise $2M in registered direct offeringMay 15, 2026 | proactiveinvestors.comNanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreakMay 11, 2026 | proactiveinvestors.comNanoViricides to Participate at D. Boral Capital Global Conference in NYCMay 7, 2026 | finance.yahoo.comNanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDAMay 7, 2026 | finance.yahoo.comNanoViricdes Surges on Winning ODD StatusMay 4, 2026 | baystreet.caNNVC stock up 17% today: What’s driving the rally?May 4, 2026 | msn.comNanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatmentMay 4, 2026 | proactiveinvestors.comDeadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricidesApril 21, 2026 | usatoday.comNanoViricides says NV-387 could address measles outbreaks as cases rise globallyApril 21, 2026 | proactiveinvestors.comNanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMIApril 11, 2026 | finance.yahoo.comNanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMIApril 11, 2026 | proactiveinvestors.comNanoViricides files for Rare Pediatric Disease Designation for Measles DrugApril 9, 2026 | finance.yahoo.comNanoViricides seeks rare pediatric disease status for measles drug NV-387April 7, 2026 | proactiveinvestors.comSmall caps wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power XApril 1, 2026 | proactiveinvestors.comNanoViricides to begin Phase II trial of MPox treatment in CongoApril 1, 2026 | proactiveinvestors.comNanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trialMarch 11, 2026 | proactiveinvestors.comNanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMIFebruary 21, 2026 | proactiveinvestors.comNanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox studyFebruary 19, 2026 | proactiveinvestors.comNanoViricides seeks FDA orphan status for MPox drugFebruary 12, 2026 | proactiveinvestors.comNanoViricides seeks orphan drug status with US FDA for measles treatmentFebruary 10, 2026 | proactiveinvestors.comNanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam TorresFebruary 9, 2026 | usatoday.comDealFlow Events: NanoViricides to Present at the 3rd Annual DealFlow Discovery ConferenceJanuary 20, 2026 | finanznachrichten.deNanoViricides to Present at the 3rd Annual DealFlow Discovery ConferenceJanuary 20, 2026 | finance.yahoo.comNanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave – NV-387 is Effective Against H3N2January 13, 2026 | usatoday.comNanoViricides highlights need for broad-spectrum antivirals amid severe flu seasonJanuary 13, 2026 | proactiveinvestors.comNanoViricides advances Phase 2 trials for broad-spectrum antiviral NV-378 in $17B market: analystsDecember 17, 2025 | proactiveinvestors.comNanoViricides files to sell 7.14 shares of common stock for holdersDecember 16, 2025 | msn.com2 Small-Cap Biotechs That Could Reward Patient InvestorsTwo small-cap biotech stocks offer high risk but significant upside for patient investors as they advance early-stage diagnostic and antiviral programs...December 12, 2025 | marketbeat.comNanoViricides signs Master Services Agreement with Only Orphans CoteDecember 1, 2025 | msn.comNanoViricides inks regulatory services deal to advance orphan drug strategy for antiviral NV-387December 1, 2025 | proactiveinvestors.comNanoViricides reports Q3 EPS (10c) vs. (23c) last yearNovember 18, 2025 | msn.comNanoViricides raises cash, moves broad-spectrum antiviral NV-387 into Phase II trialsNovember 17, 2025 | proactiveinvestors.comNanoViricides Secures $6 Million Through Securities OfferingNovember 14, 2025 | msn.comNanoViricides: Fiscal Q1 Earnings SnapshotNovember 14, 2025 | sfgate.comNanoViricides closes $6M offering to fund operationsNovember 13, 2025 | proactiveinvestors.comNanoViricides prices 3.57M shares at $1.68 in registered direct offeringNovember 11, 2025 | msn.comNanoViricides raises $6M in direct offering with institutional investorNovember 11, 2025 | proactiveinvestors.comNanoViricides receives approval to start Phase II trial of NV-387November 10, 2025 | msn.comNanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRCNovember 10, 2025 | proactiveinvestors.comNanoViricides' NV-387 shows broad antiviral potential, says ZacksNovember 7, 2025 | proactiveinvestors.comNNVC: Getting Set for Phase 2 Trial of NV-387 in MPox…November 6, 2025 | finance.yahoo.comNanoViricides targets broad-spectrum virus threats – ICYMIOctober 31, 2025 | proactiveinvestors.comNanoViricides says NV-387 shows ‘strong antiviral activity’October 22, 2025 | msn.comNanoViricides reports antiviral activity of NV-387 against measles in preclinical studiesOctober 22, 2025 | proactiveinvestors.com Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NNVC Media Mentions By Week NNVC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NNVC News Sentiment▼0.120.45▲Average Medical News Sentiment NNVC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NNVC Articles This Week▼51▲NNVC Articles Average Week Get the Latest News and Ratings for NNVC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for NanoViricides and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Innate Pharma News vTv Therapeutics News Aardvark Therapeutics News Verrica Pharmaceuticals News Tharimmune News Alpha Cognition News Turn Therapeutics News Edesa Biotech News PepGen News ALT5 Sigma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NNVC) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
